Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 8/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3591178 | 0.89 | KDM4E (0.43) | KDM4ETDP1 | |
| SCHEMBL3581488 | 0.78 | XDH (0.43) | XDHADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL13545903 | 0.76 | KDM4E (0.51) | XDHKDM4ETDP1SLC22A12 | |
| SCHEMBL3583816 | 0.75 | XDH (0.66) | XDHSLC22A12 | |
| SCHEMBL3586842 | 0.75 | KDM4E (0.40) | XDHKDM4ETDP1 | |
| SCHEMBL3581421 | 0.73 | ALDH1A1 (0.61) | XDH | |
| SCHEMBL3592443 | 0.73 | F11 (0.51) | XDHKDM4ETDP1SLC22A12 | |
| SCHEMBL3593142 | 0.73 | XDH (0.48) | XDHSLC22A12 | |
| SCHEMBL3584954 | 0.71 | XDH (0.48) | XDHSLC22A12 | |
| SCHEMBL3587212 | 0.71 | XDH (0.46) | XDHSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004459-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2128136-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004459-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | XDH, NUDT1, PNPO | XDH 1/4885ADRB2 2488/4885ADRB1 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.